Shuai-shuai R. Ge

China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.

The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.

Journal: Journal of visualized experiments : JoVE

Published: March 23, 2026

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.

Journal: Leukemia & lymphoma

Published: October 06, 2025

New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.

New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.

Journal: iScience

Published: September 14, 2025

Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations.

Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations.

Journal: Bone marrow transplantation

Published: November 10, 2024

Chidamide combined with azacitidine as a novel double epigenetic preemptive treatment for a myelodysplastic syndrome patient showing molecular relapse after allogeneic hematopoietic stem cell transplantation.

Chidamide combined with azacitidine as a novel double epigenetic preemptive treatment for a myelodysplastic syndrome patient showing molecular relapse after allogeneic hematopoietic stem cell transplantation.

Journal: Annals of hematology

Published: November 04, 2024

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.

Journal: Blood cancer journal

Published: June 24, 2024

Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.

Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.

Journal: Leukemia research

Published: January 10, 2024

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.

Journal: Blood cancer journal

Published: November 08, 2023

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study.

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study.

Journal: Blood cancer journal

Published: September 18, 2023

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.

Journal: British journal of haematology

Published: March 03, 2023

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report.

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report.

Journal: Clinical case reports

Published: July 18, 2022

Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.

Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.

Journal: Frontiers in oncology

Published: July 17, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026